Information Provided By:
Fly News Breaks for October 6, 2015
RXDX, OTIC, LBIO, FLKS, BLUE, GWPH, AMGN, CELG, ALXN
Oct 6, 2015 | 12:06 EDT
Piper Jaffray analyst Joshua Schimmer says Biopharma stocks are selling off with some spinning the eight years of exclusivity for biologics as part of the Trans Pacific Partnership as a negative for the industry. The development is a "step forward," especially since it does not over-rule the 12 years' exclusivity for the drugs in the U.S., Schimmer tells investors in an intraday research note. While the sector asked for 12 years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argues. His top picks remain Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector. Further, Schimmer writes that more names look "increasingly compelling" amid the selloff.
News For ALXN;CELG;AMGN;GWPH;BLUE;FLKS;LBIO;OTIC;RXDX From the Last 2 Days
There are no results for your query ALXN;CELG;AMGN;GWPH;BLUE;FLKS;LBIO;OTIC;RXDX